Table 3.
Regression analysis.
| Study | Time | Covariate | N | tau2 | I-squared res | Adj R-squared |
|---|---|---|---|---|---|---|
| CD4+ T-cell evaluation | D30 | Age* | 6 | 0.00 | 20.41% | 100.00% |
| HIV infection | 6 | 0.16 | 71.01% | 36.69% | ||
| Publication year | 6 | 0.14 | 62.22% | 44.50% | ||
| D60 | Adjuvant control | 5 | 0.08 | 33.08% | 58.90% | |
| Publication year | 5 | 0.07 | 22.04% | 63.78% | ||
| D210 | Adjuvant control | 5 | 0.62 | 82.24% | 53.67% | |
| Publication year | 5 | 0.92 | 88.32% | 31.71% | ||
| CD8+ T-cell evaluation | D30 | Age | 6 | 0.17 | 71.48% | 51.41% |
| D60 | Adjuvant control | 5 | 0.00 | 0.00% | 91.02% | |
| GMC | D30 | Age | 4 | 1.60 | 91.89% | 81.35% |
| Publication year | 4 | 1.60 | 91.89% | 81.35% | ||
| D60 | Age | 3 | 0.19 | 64.33% | 93.50% | |
| Publication year | 3 | 0.19 | 64.33% | 93.50% | ||
| D210 | Age | 3 | 0.84 | 90.25% | 44.50% | |
| HIV infection | 3 | 0.56 | 66.72% | 62.98% | ||
| Publication year | 3 | 0.83 | 90.25% | 44.49% | ||
| Sample size | 3 | 0.00 | 00.00% | 100% | ||
| Safety | Headache | Age | 4 | 0.00 | 0.00% | 100.00% |
| Myalgia | HIV infection | 3 | 0.00 | 0.00% | 100.00% | |
| Pain | HIV infection | 3 | 29.55 | 99.05% | 11.45% | |
| Sample size | 3 | 26.54 | 98.98% | 20.49% |
GMC, IgG geometric mean concentration;
*
P < 0.05, covariate effects were statistically significant; Tau2, REML estimate of between-study variance; I-squared res, % residual variation due to heterogeneity; Adj R-squared, Proportion of between-study variance explained. Age, Adjuvant control, HIV infection, Publication year, Sample size.